IMARA Inc. (IMRA)
| Market Cap | 244.40M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 17.35M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $14.04 |
| Previous Close | $14.05 |
| Change ($) | -0.01 |
| Change (%) | -0.07% |
| Day's Open | 14.04 |
| Day's Range | 13.80 - 14.16 |
| Day's Volume | 85,002 |
| 52-Week Range | 13.40 - 54.87 |
Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biophar...
Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of...
Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment
BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experienc...
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia
BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease Forte is the first...
Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare Conference Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global He...
BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial
Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease Highly selective, potent, small molecule...
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...
Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...
Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Company expan...
BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat...
Imara Inc. IMRA, +12.66% announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment.
Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks ...
About IMRA
Imara, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
| Industry Biotechnology | IPO Date Mar 12, 2020 |
| CEO Dr. Rahul D. Ballal Ph.D. | Employees 16 |
| Stock Exchange NASDAQ | Ticker Symbol IMRA |
Analyst Forecasts
According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 41.33, which is an increase of 194.37% from the latest price.